stay updated with our newsletter

Subscribe
Facebook Twitter Linkedin

Galectin-3 and MCP: Brain Health, Cognitive Function and Beyond

In the complex landscape of chronic disease, elevated galectin-3 is emerging as a critical, yet frequently overlooked, driver of runaway inflammation, organ fibrosis and serious long-term health consequences. As conventional strategies for modulating galectin-3 remain limited, integrative approaches are more promising, and an extensive body of research points to Modified Citrus Pectin as a potent galectin-3 inhibitor. Here’s how to create an evidence-based protocol to detect early stages of disease, influence galectin-3 and protect long-term patient health.

Gal-3: Nex-Gen Biomarker for Unmasking Disease.

Galectin-3 (gal-3) is a unique beta-galactoside binding protein, characterized by a single carbohydrate‐recognition domain along with an unstructured N-terminal domain that facilitates oligomerization. [LINK TO GALECTIN-3 JOSH HELMAN VIDEO] Located in the cytoplasm, nucleus and extracellular matrix, gal-3 is involved in numerous biological activities and cellular processes, including cell proliferation, apoptotic regulation, immune function and inflammatory repair. While gal-3 is normally found in low concentrations in the body, its pathological upregulation becomes the invisible tipping point where manageable inflammation shifts into pathological fibrosis. Through its ability to bind to cell-surface glycoproteins, gal-3 creates molecular glycan lattices that prolong the life of inflammatory receptors on cell surfaces. This prolonged, maladaptive response drives fibrosis and tissue remodeling in the heart, liver, lungs and kidneys, turning a functional organ into a fibrotic one.1, 2, 3, 4, 5, 6, 7, 8, 9, 10

The clinical significance of gal-3 is supported by a large and growing body of literature, with thousands of published studies linking its elevation to a broad spectrum of pathologies, ranging from heart failure and myocardial fibrosis to cancer metastasis and neurodegenerative disease. Higher gal-3 is associated with symptoms of depression and considered a predictor of chronic insomnia and migraines, and increased gal-3 levels are also noted in childhood epilepsy, ADHD, ASD and specific learning disorders.  [LINK TO GALECTIN-3 FULL TEXT STUDIES]

Given these far-reaching implications, gal-3 is recognized as both a critical biomarker for detecting early stages of various diseases and a potential therapeutic target for a variety of conditions. But gal-3 generally operates below the diagnostic radar, evading standard metabolic panels or traditional imaging, and high levels may go undiscovered until significant damage is done. Specific testing [LINK TO GAL-3 GUIDE] can reveal elevated gal-3 for speedy intervention. But despite its widely accepted role in serious disease, conventional medicine lacks a meaningful approach for modulating gal-3.11, 12, 13, 14, 1

Integrative Strategies for Managing Gal-3.

Because gal-3 levels correlate with the hallmarks of metabolic dysfunction, including hypertension, obesity and glucose dysregulation, diet and lifestyle modifications can address the metabolic environment that encourages its production. A Mediterranean-style diet rich in polyphenols and omega-3 fatty acids dampens systemic inflammation, improves insulin sensitivity and lipid profiles, and may directly influence proteins in the galectin family. Other research suggests limiting saturated fat may inhibit inflammatory and fibrotic processes mediated by gal-3.16, 17, 18, 19, 20

Adipose tissue is a significant source of gal-3 secretion, and reducing body weight and fat mass can decrease circulating levels of gal-3. Aerobic exercise, especially HIIT and moderate-intensity aerobic continuous training, has also been shown to blunt gal-3 expression. Because chronic HPA-axis activation and sleep deprivation are known triggers for systemic inflammation, sleep optimization is essential, and studies have identified a potential link between gal-3 and sleep disorders. Mindfulness-based stress reduction and regular meditation practices are also associated with lower concentrations of pro-inflammatory markers, including gal-3.21, 22, 23, 24, 25, 26, 27

While foundational strategies support overall health, they work slowly and may not sufficiently quench gal-3 activity once it reaches pathological levels. N-acetylcysteine, quercetin, cod fish-derived glycopeptides and other nutraceuticals aimed at modulating inflammation and fibrosis show some promise for influencing gal-3. But the most definitive data centers around Modified Citrus Pectin (MCP)—an exhaustively researched compound and powerful gal-3 inhibitor, shown to be highly effective at binding to and blocking gal-3.28, 29, 30, 31

The Molecular Blockade: MCP in Gal-3 Defense.

Citrus pectin is a soluble dietary fiber naturally found in the peel and pulp of citrus fruit. In its natural state, the long-chain carbohydrate molecules in citrus pectin are far too large to be absorbed by the human digestive tract.32, 33, 34

“The researched form of MCP is processed to a precise molecular weight and structural profile that allows it to be absorbed into the circulatory system,” says Joshua Helman, MD. “Unmodified pectin, by contrast, is too large to cross the intestinal barrier and enter systemic circulation.”

Once in the bloodstream, MCP binds directly to the carbohydrate recognition domain  at the C-terminal end of the galectin-3 protein.

“This binding competitively blocks galectin-3’s lectin activity, effectively neutralizing its capacity to initiate downstream signaling cascades,” Helman says. The result is inhibition of galectin-3’s pro-inflammatory, pro-fibrotic, and immune-dysregulating effects—the core mechanisms through which elevated galectin-3 drives a broad range of pathogenic processes and chronic disease states.”

A large body of evidence positions MCP as one of the most extensively researched natural gal-3 inhibitors available.

“More than 100 published studies have examined this specific form of MCP, consistently demonstrating its efficacy as a galectin-3 inhibitor across diverse disease models, both in vitro and in vivo,” says Helman. “The breadth of conditions studied is notable and includes multiple forms of metastatic cancer, cardiovascular disease, kidney injury and fibrosis, liver disease (including non-alcoholic fatty liver disease), and neurodegenerative conditions such as Alzheimer’s disease and age-related cognitive decline.” 35, 36, 37

Neuroinflammation and cognitive function. Elevated gal-3 is recognized as a primary driver and biomarker of neuroinflammation implicated in neurodegenerative diseases, and studies demonstrate significantly increased gal-3 levels in patients with Alzheimer’s and other cognitive disorders. MCP’s ability to inhibit gal-3 hints at a promising therapeutic target for managing neuroinflammation and cognitive decline. In animal models, MCP lowered brain inflammation and alleviated cognitive impairments in Alzheimer’s-type dementia, along with exhibiting significant antioxidant potential. Research also suggests MCP defends against diabetes-related cognitive decline: animal models show treatment with MCP improved learning and memory and lessened cognitive loss associated with diabetes. Other studies highlight its neuroprotective effects on post-stroke cognitive impairment. MCP was found to block gal-3 and hinder blood-brain barrier disruption following strokes and traumatic brain injuries, decreasing brain edema and minimizing neurological impairment. In animal models, MCP significantly reduced neurological deficit scores, brain water content and infarction volume, alleviating cell injury in the cerebral cortex.38, 39, 40, 41, 42, 43, 44, 45

Cardiovascular wellness. Gal-3 is an FDA-approved prognostic biomarker in heart failure, and elevated levels are linked with adverse long-term cardiovascular outcomes, myocardial fibrosis and atherosclerosis, and predictive of heart failure. By binding to gal-3—known to accelerate cardiac remodeling, inflammation and fibrosis—MCP exhibits multiple beneficial effects on the heart. Studies suggest treatment with MCP can slow the progression of heart failure and protect against myocardial injury. In animal models, MCP decreased cardiac inflammation, blunted collagen deposition, mediated vascular remodeling and cardiac fibrosis and ameliorated cardiac dysfunction. MCP has been shown to reduce atherosclerotic lesions, blocking leukocyte adhesion to endothelial cells. Additionally, MCP inhibited TLR4/MyD88/NF-κB signaling and decreased the expression of IL-1β, IL-18 and TNF-α—implicated in the pathogenesis of heart failure. Other research suggests MCP could prevent and delay aortic dissection, impede its progression and improve patient outcomes.46, 47, 48, 49, 50, 51, 52, 53, 54

Cancer protection.  In cancer, gal-3 promotes tumor cell survival and metastatic spread, allowing cancer cells to aggregate, travel through the bloodstream and adhere to new organ sites. By blocking gal-3, MCP disrupts cancer cell adhesion, migration, aggregation and proliferation, and studies support its anti-cancer and anti-metastatic properties. In preclinical trials of melanoma, breast and colon cancers, MCP inhibited several rate-limiting steps of metastasis, including cell adhesion and angiogenesis. In further research, MCP was shown to be effective against prostate, colon, breast, ovarian, liver, multiple myeloma, melanoma and other cancers. Additional data suggests MCP may enhance the effectiveness of certain chemotherapy drugs and help overcome treatment resistance in some solid tumors.55, 56, 57, 58, 59, 60, 61, 62

Renal health. Elevated gal-3 is known to fuel inflammation and fibrosis in renal diseases, and MCP’s ability to inhibit gal-3 has been shown to lower inflammation, mitigate kidney damage and improve kidney function. In animal models of acute kidney injury, MCP decreased gal-3 expression and reduced renal fibrosis, apoptosis, cellular proliferation and chronic nephropathy.63, 64, 65, 66

Heavy metal detoxification. MCP is considered an effective natural chelator for removing heavy metals from the body without impacting essential minerals. In one trial, oral administration of MCP significantly increased urinary excretion of toxic metals, including arsenic, cadmium and lead, in subjects with a normal load of metals. Unlike some chemical chelators, MCP does not appear to deplete calcium, magnesium, zinc, selenium, iron or other vital minerals.67, 68, 69

Immune support. Gal-3 has various effects on immune cell regulation, and elevated levels are known to impact immune function, suppress immune surveillance, and influence the pathogenesis of autoimmune diseases. Ongoing research supports MCP’s immunomodulatory properties and its ability to affect both innate and adaptive immune responses. In studies, MCP was shown to modulate cytokine release and significantly activate several types of human immune cells, including T-cells, B-cells and natural killer cells. In other research, MCP combined with probiotics improved gut microbiota integrity, crucial for robust and balanced immunity.70, 71, 72, 73, 74

 

Free Download:

Galectin-3: Culprit Biomarker of Inflammation, Fibrosis & Chronic Disease – A Clinicians Guide

 

References:

  1. Cummings RD, Liu FT. Galectins. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 33.
  2. Pia Lenza M et al. Structural Insights Into Galectin-3 Recognition of a Selenoglycomimetic. ChemMedChem. 2025 May 19;20(10):e202401005.
  3. Verkerke H et al. Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions. Methods Mol Biol. 2022;2442:1-40.
  4. Martuszewski A et al. Galectin-3 in Cardiovascular Health: A Narrative Review Based on Life’s Essential 8 and Life’s Simple 7 Frameworks. Curr Issues Mol Biol. 2025 May 6;47(5):332.
  5. Bouffette S et al. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol Sci. 2023 Aug;44(8):519-531.
  6. de Oliveira FL et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 2015 Aug;240(8):1019-28.
  7. Madrigal-Matute J et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc. 2014 Aug 5;3(4):e000785.
  8. van den Berg PF et al. Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure. JACC CardioOncol. 2023 Jul 11;5(4):445-453.
  9. Nakajima K et al. Galectin-3: an immune checkpoint target for musculoskeletal tumor patients. Cancer Metastasis Rev. 2021 Mar;40(1):297-302.
  10. Li T et al. Galectin-3 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension. Aging Dis. 2019 Aug 1;10(4):731-745.
  11. Dong R et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018 Feb;41(2):599-614.
  12. Hara A et al. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. 2020 Mar 3;10(3):389.
  13. Sciacchitano S et al. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int J Mol Sci. 2018 Jan 26;19(2):379.
  14. de Boer RA et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012 Jul;272(1):55-64.
  15. Sygitowicz G et al. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. Biomolecules. 2021 Dec 29;12(1):46.
  16. Menini S et al. Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis. Oxid Med Cell Longev. 2016;2016:9618092.
  17. Danese E et al. Physiologic determinants of serum galectin-3 in a general healthy population. Ann Res Hosp 2017;1:35.
  18. Fekete M et al. Mediterranean Diet, Polyphenols, and Neuroprotection: Mechanistic Insights into Resveratrol and Oleuropein. Nutrients. 2025 Dec 16;17(24):3929.
  19. Xiao Y et al. Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease. Front Nutr. 2023 Oct 10;10:1225946.
  20. Scaglione S et al. Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk. Nutrients. 2025 Jan 20;17(2):358.
  21. Pejnovic NN et al. Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets. Adipocyte. 2013 Oct 1;2(4):266-71.
  22. Rhodes DH et al. Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function. Obesity (Silver Spring). 2013 Feb;21(2):310-9.
  23. Martínez-Martínez E et al. Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes (Lond). 2016 Jun;40(6):1034-8.
  24. Rodrigues KL et al. Aerobic exercise training attenuates cardiac inflammation and fibrosis in mice with type 2 diabetes and inhibits the advanced glycation end products pathway. Diabetol Metab Syndr. 2026 Jan 7;18(1):46.
  25. Keyhani D et al. Effect of High-Intensity Interval Training Versus Moderate-Intensity Aerobic Continuous Training on Galectin-3 Gene Expression in Postmenopausal Women: A Randomized Controlled Trial. J Aging Phys Act. 2020 Jul 17;28(6):987-995.
  26. Andersen ML et al. Unlocking the role of Galectin-3: Implications for sleep disorders and health. Sleep Med. 2024 Dec;124:110-114.
  27. Guo L et al. Sleep-Disturbance-Induced Microglial Activation Involves CRH-Mediated Galectin 3 and Autophagy Dysregulation. Cells. 2022 Dec 30;12(1):160.
  28. Wasyanto T et al. Effect of Oral N-Acetylcysteine Supplementation on the Immunity System in Patients with Acute Myocardial Infarction. Acta Med Indones. 2019 Oct;51(4):311-317.
  29. Li H et al. Quercetin Attenuates Atherosclerotic Inflammation by Inhibiting Galectin-3-NLRP3 Signaling Pathway. Mol Nutr Food Res. 2021 Aug;65(15):e2000746.
  30. Guha P et al. Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5052-7.
  31. Eliaz I, Raz A. Pleiotropic Effects of Modified Citrus Pectin. Nutrients. 2019 Nov 1;11(11):2619.
  32. Lara-Espinoza C et al. Pectin and Pectin-Based Composite Materials: Beyond Food Texture. Molecules. 2018 Apr 18;23(4):942.
  33. Lau ES et al. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. JACC Basic Transl Sci. 2021 Jan 6;6(1):12-21.
  34. Gunning AP et al. Recognition of galactan components of pectin by galectin-3. FASEB J. 2009 Feb;23(2):415-24.
  35. Venzon SS et al. Physicochemical properties of modified citrus pectins extracted from orange pomace. J Food Sci Technol. 2015 Jul;52(7):4102-12.
  36. Xu GR et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomed Pharmacother. 2020 Jun;126:110071.
  37. Lin C et al. Structurally reprogrammed modified citrus pectin (MCP) enables potentiated galectin-3 sequestration and injectable carboxymethyl chitosan/berberine hydrogel construction for osteoarthritis immunotherapy. Mater Today Bio. 2025 Sep 20;35:102330.
  38. Srejovic I et al. Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior. Biomolecules. 2020 May 21;10(5):798.
  39. Tan Y et al. Galectin-3: a key player in microglia-mediated neuroinflammation and Alzheimer’s disease. Cell Biosci. 2021 Apr 27;11(1):78.
  40. Wang X et al. Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer’s Disease. Am J Alzheimers Dis Other Demen. 2015 Dec;30(8):729-32.
  41. Akgöl J et al. Assessment of Modified Citrus Pectin’s Effects on Dementia in the Scopolamine-Induced Alzheimer’s Model in Adult Male Wistar Rats. Curr Issues Mol Biol. 2024 Dec 11;46(12):13922-13936.
  42. Ma S et al. Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level. J Diabetes Investig. 2020 Sep;11(5):1295-1302.
  43. Yin Q et al. Pharmacological Inhibition of Galectin-3 Ameliorates Diabetes-Associated Cognitive Impairment, Oxidative Stress and Neuroinflammation in vivo and in vitro. J Inflamm Res. 2020 Sep 15;13:533-542.
  44. Cui Y et al. Modified Citrus Pectin Alleviates Cerebral Ischemia/Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation via TLR4/NF-ĸB Signaling Pathway in Microglia. J Inflamm Res. 2022 Jun 9;15:3369-3385.
  45. Nishikawa H et al. Modified Citrus Pectin Prevents Blood-Brain Barrier Disruption in Mouse Subarachnoid Hemorrhage by Inhibiting Galectin-3. Stroke. 2018 Nov;49(11):2743-2751.
  46. de Boer RA et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009 Sep;11(9):811-7.
  47. Ho JE et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012 Oct 2;60(14):1249-56.
  48. Hrynchyshyn N et al. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis. 2013 Oct;106(10):541-6.
  49. Martínez-Martínez E et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015 Oct;66(4):767-75.
  50. Lu Y et al. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice. Mol Med Rep. 2017 Jul;16(1):647-653.
  51. Nachtigal M et al. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol. 2008 Jan;172(1):247-55.
  52. Shih CC et al. Modified citrus pectin protects aortic dissection development involving macrophage pyroptosis. Arch Biochem Biophys. 2025 Jul;769:110428.
  53. Calvier L et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015 Jan;3(1):59-67.
  54. Suthahar N et al. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics. 2018 Jan 1;8(3):593-609.
  55. Glinskii OV et al. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 2005 May;7(5):522-7.
  56. Ornelas AC et al. Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment. Onco Ther. 2022;9(2):43-55.
  57. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009 Sep 28;344(14):1788-91.
  58. Hayashi A et al. Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumor growth in Balb-c mice. Altern Med Rev. 2000 Dec;5(6):546-52.
  59. Nangia-Makker P et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62.
  60. Sathisha UV et al. Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources. Glycoconj J. 2007 Nov;24(8):497-507.
  61. Johnson KD et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia. 2007 Aug;9(8):662-70.
  62. Vityala Y. Enhancing the Efficacy of Radiation Therapy and Chemotherapy in Cancer Treatment with Modified Citrus Pectin and Metformin. Asian J Pharm. 2024; 18(01).
  63. Li HY et al. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci Rep. 2018 Dec 18;38(6):BSR20181803.
  64. Kolatsi-Joannou M et al. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One. 2011;6
  65. Frenay AR et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F500-9.
  66. Martinez-Martinez E et al. Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage. PLoS One. 2016 Nov 9;11(11):e0166272.
  67. Eliaz I et al. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytother Res. 2006 Oct;20(10):859-64.
  68. Zhao ZY et al. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008 Jul-Aug;14(4):34-8.
  69. Eliaz I et al. Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification–five case reports. Forsch Komplementmed. 2007 Dec;14(6):358-64.
  70. Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023 Aug;23(8):479-494.
  71. Díaz-Alvarez L, Ortega E. The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens. Mediators Inflamm. 2017;2017:9247574.
  72. Merheb R et al. Immunomodulatory effect of natural and modified Citrus pectin on cytokine levels in the spleen of BALB/c mice. Int J Biol Macromol. 2019 Jan;121:1-5.
  73. Odun-Ayo F et al. The effect of modified citrus pectin-probiotic on faecal lactobacilli in Balb/c mice. Food Sci Technol. 2017;37:478–482.
  74. Ramachandran C et al. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med. 2011;11:59.

 

Related Articles